
Please visit answersincme.com/ZPW860 to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by David R. Staskin, MD. In this activity, an expert in urology discusses strategies to diagnose and individualize treatment for overactive bladder (OAB) in patients with benign prostatic hyperplasia (BPH), including the role of beta-3 adrenergic agonists and guideline-based care. Upon completion of this activity, participants should be better able to: Identify strategies to diagnose overactive bladder (OAB) in patients with benign prostatic hyperplasia (BPH); Assess the evidence for beta-3 adrenergic agonists in the treatment of OAB among patients with BPH; and Outline approaches to tailor OAB treatment for individual patients with BPH.
Podzilla Summary coming soon
Sign up to get notified when the full AI-powered summary is ready.
Free forever for up to 3 podcasts. No credit card required.

It’s Not "Just Hives": Advancing Targeted Care in Chronic Spontaneous Urticaria

From Evidence to Impact: Leveraging the Latest Data to Elevate Standards and Patient Outcomes in mHSPC

Translating Evidence Into Practice: Optimizing Chemotherapy-Free Intervals and Sequencing in mCRC

Oncology - Pathology Dialogues: Evolving Diagnostic Pathways to Expand Treatment of Extrapulmonary Neuroendocrine Neoplasms
Free AI-powered recaps of CME in Minutes: Education in Primary Care and your other favorite podcasts, delivered to your inbox.
Free forever for up to 3 podcasts. No credit card required.